Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPSON: Radium-223 and Docetaxel Sequencing in mCRPC
NCT03230734Phase 2Active, not recruiting
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2017
- Primary completion
- Jul 2025
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Sep 2017; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03230734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03230734.